We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases / Novasep announces strong growth in 2020, in an exceptional context, demonstrating the robustness of its strategic model

Novasep announces strong growth in 2020, in an exceptional context, demonstrating the robustness of its strategic model

Novasep announces strong growth in 2020, in an exceptional context, demonstrating the robustness of its strategic model
05 May 2021

• The Group recorded sales of €394M (+46%) and an EBITDA of €63M (+174%)
• Novasep has now completed its Rise-2 strategic plan, a full two years ahead of schedule
• Full deleveraging is in progress following the divestment of the Viral Vector Manufacturing Business in early 2021

 

Lyon, France, May 5, 2021 – Novasep, a major player in services and technologies for the life sciences industry, presents its 2020 financial performance, announcing the completion of its Rise-2 strategic plan two years ahead of schedule.

Novasep's results for 2020 demonstrate extraordinarily strong growth. Total sales revenue amounted to 394 million euros, while EBITDA reached 63 million euros.

"These results are exceptional, especially in the context of the health and economic crisis that the world is going through. They reflect the trust and commitment of our customers, the level of confidence our shareholders have placed in us over many years, the relevance of our strategic model, and the remarkable commitment of our employees under extraordinary circumstances, to whom I would like to express my special thanks," says Dr. Michel Spagnol, Novasep’s CEO. “This operating performance, combined with the business divestments announced in January – the sale of the Gene Therapy and Viral Vectors business and the planned sale of our Equipment service line – will enable the Group to fully deleverage by the end of July.”

Novasep's new financial situation closes the Rise-2 strategic cycle, which aimed to double the group's profitability, a full two years ahead of plan. Group management is currently working on the next chapter of Novasep's strategic development, which will build on new opportunities for growth through acquisitions.

“We are currently finalizing this new strategic growth plan, with the aim of consolidating the Group's international positions on the pharmaceutical market”, concludes Dr. Michel Spagnol. "This new chapter will be strongly consistent with our areas of expertise and technological strength, motivated by the desire to offer innovative therapeutic solutions to our customers and to patients."

About Novasep
Novasep provides cost-effective solutions for the sustainable production of molecules for the life sciences. Novasep's unique offering includes process development & contract manufacturing services, purification equipment and turnkey processes to serve pharmaceutical, biopharmaceutical, fine chemical, food and functional ingredients as well as fermentation and chemical commodities industries. https://www.novasep.com

Press contact
Thomas Goldberg
Communication Project Manager 
press@novasep.com

Novasep Icon PDF 2021 05 05_Press Release_Novasep FY 2020 Results_EN

Novasep Icon PDF 2021 05 05_Press Release_Novasep FY 2020 Results_FR

Novasep Icon PDF 2021 05 05_Press Release_Novasep FY 2020 Results_DE

 


Back to full list of events

You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Your brochure is ready!

X

You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Give us your feedback!